Evidence map›Paper›PMID 41258634›Full record

ReviewDiscover oncology2025

Potential function of miRNA as a diagnostic biomarker for human ovarian cancer.

Furong Liu, Zihao An, Chao Tang, Xiaoliang Han

Abstract readReview
In one paragraph

Review in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Furong LiuDepartment of Pharmacy, Affiliated Hospital of Shaoxing University, Shaoxing, 312000, China.
Zihao AnNational Clinical Research Center for Child Health of Children's Hospital, Zhejiang University School of Medicine, Hangzhou, 310052, China.
Chao TangNational Clinical Research Center for Child Health of Children's Hospital, Zhejiang University School of Medicine, Hangzhou, 310052, China. chtang@zju.edu.cn.
Xiaoliang HanChest Surgery, Affiliated Hospital of Shaoxing University, Shaoxing, 312000, China. 171053822@qq.com.

Funding

Shaoxing Health Science and Technology Plan 2024SKY073
6 · The paper itself

Abstract

Ovarian cancer (OC), a common gynecological malignancy, seriously threatens the lives and health of women. Though several serological markers are used for the early diagnosis of OC, most have low specificity and sensitivity. Micro-RNAs (miRNAs), a family of non-coding RNAs that function at the post-transcriptional level, are emerging as specific biomarkers to achieve effective diagnosis and treatment strategies for OC. In this review, we summarize the current investigations on miRNAs in the detection and monitoring of OC and discuss the molecular mechanisms that may provide a reliable detection method for OC at early stages. Thus, miRNAs are promising biomarkers, suggesting their potential as therapeutic targets in OC.

Indexed as

BiomarkermiRNAMolecular mechanismOvarian cancer

Identifiers

PMID41258634
PMCPMC12748454

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.